Moderna
MRNA
694 hedge funds and large institutions have $8B invested in Moderna in 2025 Q1 according to their latest regulatory filings, with 86 funds opening new positions, 263 increasing their positions, 208 reducing their positions, and 129 closing their positions.
26% more repeat investments, than reductions
Existing positions increased: 263 | Existing positions reduced: 208
1.13% more ownership
Funds ownership: 72% → 73.13% (+1.1%)
7% less funds holding
Funds holding: 747 → 694 (-53)
13% less funds holding in top 10
Funds holding in top 10: 8 → 7 (-1)
22% less call options, than puts
Call options by funds: $801M | Put options by funds: $1.03B
31% less capital invested
Capital invested by funds: $11.5B → $8B (-$3.52B)
33% less first-time investments, than exits
New positions opened: 86 | Existing positions closed: 129
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
D.E. Shaw & Co
New York
|
+$137M |
| 2 |
Two Sigma Investments
New York
|
+$134M |
| 3 |
Two Sigma Advisers
New York
|
+$131M |
| 4 |
Morgan Stanley
New York
|
+$113M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$87.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$495M |
| 2 |
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
|
-$105M |
| 3 |
Norges Bank
Oslo,
Norway
|
-$42.6M |
| 4 |
Pictet Asset Management
Carouge,
Switzerland
|
-$38.6M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$36.2M |
MRNA Hedge Fund Activity: Q1 2025 in Review
694 of the 7,472 institutional investors tracked by Wall St. Rank reported a position in Moderna (MRNA) for Q1 2025, worth a combined $8B — down 31% from $11.5B a quarter earlier.
Sellers outnumbered buyers: 129 funds closed out of MRNA and 86 opened new positions — a net loss of 43 holders — while 208 trimmed existing stakes and 263 added.
The largest buyer was D.E. Shaw & Co, adding an estimated $137M. The largest seller was Baillie Gifford & Co, cutting an estimated $495M.
- 694 institutional investors held Moderna (MRNA) as of Q1 2025, down from 747 in Q4 2024.
- Funds reported $8B of Moderna stock for Q1 2025, down 31% quarter-over-quarter.
- 86 funds opened new Moderna positions in Q1 2025 and 129 closed out, a net change of -43 holders.
- The largest Moderna buyer in Q1 2025 was D.E. Shaw & Co, an estimated $137M added.
- The largest Moderna seller in Q1 2025 was Baillie Gifford & Co, an estimated $495M sold.
Based on aggregated 13F filings for Q1 2025.